PYPD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.330

-69.16%

-0.265

-62.14%

-0.260

-66.67%

Estimates Revision

The market is revising No Change the revenue expectations for PolyPid Ltd. (PYPD) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 39.55%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-14.85%

In Past 3 Month

Stock Price

Go Up

+39.55%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast PYPD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PYPD is 11.00 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

11.00

High

13.00

Current: 0.000

Low

9.00

Averages

11.00

High

13.00

Roth Capital

Buy

downgrade

$10 -> $9

2025-11-13

Reason

Roth Capital

Price Target

$10 -> $9

2025-11-13

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on PolyPid to $9 from $10 and keeps a Buy rating on the shares following the Q3 report. The firm expects a positive pre-new drug application meeting and a potential filing submission in the first half of 2026 for PolyPid. Given that D-PLEX100 "enjoys multiple designations" from the FDA, it should get a six-month review, the analyst tells investors in a research note.

Roth Capital

Buy

maintain

$9 -> $10

2025-08-14

Reason

Roth Capital

Price Target

$9 -> $10

2025-08-14

maintain

Buy

Reason

Roth Capital raised the firm's price target on PolyPid to $10 from $9 and keeps a Buy rating on the shares after meeting with its management following the company's Q2 results. The firm expects a fairly uneventful pre-NDA meeting given solid D-PLEX100 clinical data, which Roth believes is poised to transform the treatment paradigm in SSI associated with colorectal cancer surgery, providing benefits to patients and healthcare systems, the analyst tells investors in a research note.

Craig-Hallum

Chase Knickerbocker

Buy

downgrade

$15 -> $13

2025-08-14

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$15 -> $13

2025-08-14

downgrade

Buy

Reason

Craig-Hallum analyst Chase Knickerbocker lowered the firm's price target on PolyPid to $13 from $15 and keeps a Buy rating on the shares following quarterly results. The biggest highlight of the quarter was the positive Shield 2 data and the following warrant inducement providing $27M and extending the cash runway into the second half of 2026, allowing them to pursue a partnership for U.S. rights to D-Plex100, with active discussions ongoing, the firm says. A development milestone from the Advanz partnership in the EU may also be coming up, Craig-Hallum adds.

Roth Capital

Buy

downgrade

$12 -> $9

2025-06-19

Reason

Roth Capital

Price Target

$12 -> $9

2025-06-19

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on PolyPid to $9 from $12 and keeps a Buy rating on the shares. The firm is updating its model after the company has executed a new financing agreement that will infuse $27M worth of cash into its coffers, allowing PolyPid to schedule a pre-NDA, New Drug Application, meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026, the analyst tells investors in a research note.

Citizens JMP

Outperform

downgrade

$16 -> $14

2025-06-18

Reason

Citizens JMP

Price Target

$16 -> $14

2025-06-18

downgrade

Outperform

Reason

Citizens JMP lowered the firm's price target on PolyPid to $14 from $16 and keeps an Outperform rating on the shares after the company announced that it anticipates gross proceeds of $26.7M from the exercise of 7.6M existing warrants that have been re-priced to a $3.50 exercise price and that it will issue another 7.6M warrants at $4.50. The firm's confidence is bolstered in the potential for D-PLEX100 to get to market following the warrant exercise, the analyst tells investors in a research note.

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$12 -> $9

2025-06-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$12 -> $9

2025-06-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on PolyPid to $9 from $12 primarily due to a higher forecasted share count in Q1 2026, while keeping a Buy rating on the shares. The firm notes PolyPid has executed a new financing agreement that will infuse about $27M worth of cash into its coffers, allowing the company to schedule a pre-NDA meeting with the FDA in the coming months and potentially file the D-PLEX100 NDA in the first half of 2026.

Valuation Metrics

The current forward P/E ratio for PolyPid Ltd (PYPD.O) is -3.92, compared to its 5-year average forward P/E of -1.94. For a more detailed relative valuation and DCF analysis to assess PolyPid Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.94

Current PE

-3.92

Overvalued PE

-0.58

Undervalued PE

-3.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.77

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.37

Undervalued EV/EBITDA

-1.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

47.17

Current PS

0.00

Overvalued PS

245.02

Undervalued PS

-150.68

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PYPD News & Events

Events Timeline

No data

News

5.0

2025-12-16NASDAQ.COM

PolyPid Names Brooke Story as Board Chairman

9.5

2025-12-03Newsfilter

PolyPid Receives FDA Support for D-PLEX100 NDA Submission

4.0

2025-11-13Benzinga

Roth Capital Reaffirms Buy Rating on PolyPid, Reduces Price Target to $9

People Also Watch

Frequently Asked Questions

What is PolyPid Ltd (PYPD) stock price today?

The current price of PYPD is 4.64 USD — it has decreased -0.22 % in the last trading day.

What is PolyPid Ltd (PYPD)'s business?

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

What is the price predicton of PYPD Stock?

What is PolyPid Ltd (PYPD)'s revenue for the last quarter?

PolyPid Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is PolyPid Ltd (PYPD)'s earnings per share (EPS) for the last quarter?

PolyPid Ltd. EPS for the last quarter amounts to -0.37 USD, decreased -69.67 % YoY.

What changes have occurred in the market's expectations for PolyPid Ltd (PYPD)'s fundamentals?

How many employees does PolyPid Ltd (PYPD). have?

PolyPid Ltd (PYPD) has 57 emplpoyees as of January 10 2026.

What is PolyPid Ltd (PYPD) market cap?

Today PYPD has the market capitalization of 77.19M USD.